−1.525CHF
−49.98 MCHF
311.26 MCHF
13.30 M
About POLYPEPTIDE GROUP
Sector
Industry
CEO
Juan-José Gonzalez
Website
Headquarters
Baar
Employees (FY)
1.27 K
Founded
1996
ISIN
CH1110760852
FIGI
BBG0100P02W2
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 8H0 is 29.371 CHF — it has increased by 8.72% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange POLYPEPTIDE GROUP stocks are traded under the ticker 8H0.
POLYPEPTIDE GROUP is going to release the next earnings report on Aug 13, 2024. Keep track of upcoming events with our Earnings Calendar.
8H0 stock is 8.11% volatile and has beta coefficient of 1.75. Check out the list of the most volatile stocks — is POLYPEPTIDE GROUP there?
POLYPEPTIDE GROUP revenue for the last quarter amounts to 128.77 M CHF despite the estimated figure of 126.49 M CHF. In the next quarter revenue is expected to reach 149.80 M CHF.
Yes, you can track POLYPEPTIDE GROUP financials in yearly and quarterly reports right on TradingView.
8H0 net income for the last quarter is −16.45 M CHF, while the quarter before that showed −33.77 M CHF of net income which accounts for 51.30% change. Track more POLYPEPTIDE GROUP financial stats to get the full picture.
Today POLYPEPTIDE GROUP has the market capitalization of 969.30 M, it has increased by 11.11% over the last week.
Like other stocks, 8H0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade POLYPEPTIDE GROUP stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 1.27 K employees. See our rating of the largest employees — is POLYPEPTIDE GROUP on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So POLYPEPTIDE GROUP technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating POLYPEPTIDE GROUP stock shows the strong buy signal. See more of POLYPEPTIDE GROUP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on POLYPEPTIDE GROUP future price: according to them, 8H0 price has a max estimate of 30.15 CHF and a min estimate of 16.85 CHF. Read a more detailed POLYPEPTIDE GROUP forecast: see what analysts think of POLYPEPTIDE GROUP and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. POLYPEPTIDE GROUP EBITDA is −10.62 M CHF, and current EBITDA margin is −3.27%. See more stats in POLYPEPTIDE GROUP financial statements.